Testosterone in women is one of the most under-discussed pieces of the perimenopause picture, partly because most testosterone content online is built for men, and partly because licensing for women's testosterone varies wildly by country. The signal that something has changed is rarely "I want sex less" in the tabloid sense — it's more often a quieter loss of drive, of muscle response to training, of orgasm intensity, of the internal "let's go" that you didn't know was a hormone until it wasn't there.
What it does
Ovaries and adrenal glands both produce testosterone, and across the reproductive years women make more testosterone by mass than estrogen. It contributes to libido, muscle maintenance, bone density, energy, mental clarity, and a sense of drive that's hard to describe until it's gone.
What changes in perimenopause
Testosterone declines gradually from your thirties onward, not in the dramatic way estrogen and progesterone do at perimenopause. But the loss compounds, and surgical menopause (ovaries out) drops it sharply overnight.
Where you'll feel it
Loss of libido that isn't about the relationship. Loss of orgasm intensity. Muscle that doesn't respond to training the way it used to. A flatness or 'meh' quality that's distinct from depression. Less get-up-and-go.
What the appointment language sounds like
Testosterone for women is licensed for low libido (HSDD) in some countries and prescribed off-label in others, usually as a low-dose transdermal cream or gel. The British Menopause Society has clear guidance; access varies a lot by country and by who you see.
Why women's testosterone is so under-discussed
The third hormone that almost no one explains
Across the reproductive years, women produce more testosterone by mass than they do estrogen. Most of it is made in the ovaries and adrenal glands, and most of it is bound to a protein called sex-hormone-binding globulin (SHBG) — only the small unbound fraction is biologically active. Levels typically peak in the mid-20s and then drift gradually downward; by the late 40s most women have about half the free testosterone they had at 25.
Surgical menopause (both ovaries removed) is the exception — testosterone drops sharply within days, not years. That is one of the reasons surgical menopause feels qualitatively different from natural menopause and one of the strongest indications for testosterone replacement, even where libido is not the headline complaint.
Hypoactive sexual desire disorder (HSDD), the licensed indication
What the evidence supports, and where it stops
The strongest randomised-trial evidence for testosterone in women is for HSDD in postmenopausal women: a modest but real improvement in sexual desire, arousal, orgasm and satisfaction, with a low side-effect profile at physiological female doses. The 2019 Global Position Statement on Testosterone for Women is the international reference for prescribing.
Outside HSDD — for energy, mood, muscle, brain, or 'just feeling like myself again' — the evidence is much thinner. Some women describe meaningful improvements; others don't notice. The honest framing is 'libido has the data; everything else is plausible mechanism plus individual response, prescribed cautiously and reviewed regularly'.
Dose, route and monitoring
Female-physiological doses, transdermal, and an annual blood-level check
Female testosterone is prescribed at roughly one-tenth the male dose, almost always as a transdermal cream or gel applied to the lower abdomen or outer thigh. Pellets and injections are not recommended for women in any major society guideline because they reliably overshoot physiological levels and cause side effects that are slow to reverse.
A baseline and 3-to-6-month total-testosterone blood level keeps the dose in the female-physiological range. Acne, mild hair growth at the application site, and rarely scalp hair thinning are the most common side effects; they almost always settle when the dose is reduced.
Pellets and injections — why the guidelines say no
The pellet conversation, in plain English
Hormone pellets are small compounded implants placed under the skin of the hip every three to six months. They've been heavily marketed to women in the United States and, increasingly, the UK and Australia, often with language about 'bioidentical', 'optimization' and 'restoring youthful levels'. The marketing is louder than the evidence.
The reason every major menopause and endocrine society — NAMS / The Menopause Society, the British Menopause Society, the Endocrine Society, the International Menopause Society — recommends against pellets for women is mechanical, not ideological. Once a pellet is implanted, the dose can't be adjusted and can't be retrieved. Blood testosterone routinely lands two to ten times above the female physiological range in the weeks after insertion, then drifts down — so most women spend most of the cycle either too high or too low. Side effects from supraphysiologic levels (acne, hair growth, scalp thinning, voice change, clitoromegaly) take months to resolve because the hormone is still being released from the implant.
Pellets are also almost always compounded, which means they sit outside the regulatory framework that governs licensed HRT — no batch testing for dose accuracy, no required adverse-event reporting, no standardised labelling. The FDA, NAMS and the Endocrine Society have all issued specific statements that compounded BHRT pellets should not be used as a routine alternative to regulated HRT.
None of this means the women who feel better on pellets are imagining it — testosterone in the supraphysiologic range does produce a noticeable energy and libido lift. The argument is that the same benefit is achievable, more safely and more reversibly, with a daily transdermal cream at female-physiological doses. If a clinician is recommending pellets, fair questions to ask are: what's your plan if I get side effects in the first month, how will we monitor levels, and why not start with a transdermal route I can stop tomorrow.
The evidence behind this page
What the studies and guidelines actually say
Curated, primary-source-or-guideline only. Each card opens the original paper or position statement so you can read it for yourself.
Testosterone improves sexual desire, arousal, orgasm and satisfaction in postmenopausal women with HSDD; evidence outside the sexual-function indication is limited.
Davis et al, on behalf of the IMS, NAMS, ESE, ENDO, RCOG, AMS, FSRH and others
The international consensus statement endorsed by every major menopause and endocrine society. The reference document for prescribing.
Read the sourceA meta-analysis of randomised trials found a small-to-moderate effect size of testosterone on sexual function in postmenopausal women, with no signal for serious adverse events at female-physiological doses.
Islam et al
Read the sourcePellet and injection routes for women's testosterone reliably exceed physiological levels and are not recommended in major guidelines.
Compounded bioidentical hormone therapy, including pellet implants, is not recommended as a routine alternative to FDA-approved HRT; concerns include lack of dose standardisation, absent adverse-event reporting, and supraphysiologic peaks.
Subcutaneous testosterone pellets in women produce serum testosterone concentrations several-fold above the female physiological range, with associated androgenic side effects.
Surgical menopause produces an abrupt drop in circulating testosterone, in contrast to the gradual decline of natural menopause.